Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NOVAVAX INCNVAX · Entity 4632 | President, R&D | March 06, 2023 | March 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NOVAVAX INC
Report date March 06, 2023 · Filed March 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,473 |
Reported balance
After 2023-03-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-03-06 · Purchase · Acquired 3,000 · Balance 11,473 F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.2658 to $7.65, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. F2: Includes 464 shares acquired on January 31, 2023 under the Company's Amended and Restated 2013 Employee Stock Purchase Plan, as amended. |
| Common StockSEC Table I · non-derivative | Direct | 13,473 |
Reported balance
After 2023-03-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-03-07 · Purchase · Acquired 2,000 · Balance 13,473 F3: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.0089 to $7.0594, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 14,473 |
Reported balance
After 2023-03-10 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2023-03-10 · Purchase · Acquired 1,000 · Balance 14,473 F4: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.45 to $6.55, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 20,771 |
Reported balance
After 2023-03-10 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2023-03-10 · Exercise / conversion · Acquired 6,298 · Balance 20,771 F5: The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs"). |
| Common StockSEC Table I · non-derivative | Direct | 18,339 |
Reported balance
After 2023-03-10 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2023-03-10 · Tax withholding · Disposed 2,432 · Balance 18,339 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,596 |
Reported balance
After 2023-03-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-10 · Exercise / conversion · Disposed 6,298 · Balance 12,596 F6: Each RSU represents a contingent right to receive one share of the Company common stock. F7: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.2658 to $7.65, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F2: Includes 464 shares acquired on January 31, 2023 under the Company's Amended and Restated 2013 Employee Stock Purchase Plan, as amended.
F3: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.0089 to $7.0594, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F4: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.45 to $6.55, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F5: The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs").
F6: Each RSU represents a contingent right to receive one share of the Company common stock.
F7: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 619 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · derivative · entry 27 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,480 Underlying: Common Stock · 619 shares Expires 2026-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F22 · derivative.exercise_date: Vesting of the shares subject to this option grant under the Plan were subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which twenty-five percent (25%) of the shares vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments on the first of each month over the following three (3) years, subject to continued employment through such vesting date, and (2) a performance-based vesting requirement, pursuant to which 33.33%, 33.33%, and 33.34% of the shares vested, if at any time during the four-year period from the November 14, 2016 grant date, the volume-weighted average stock price of Novavax, Inc.'s common stock met or exceeded $80.00, $120.00, or $160.00, respectively, for twenty (20) consecutive trading days. Novavax Inc.'s common stock did not meet $160.00 for twenty (20) consecutive trading days and therefore 2,918 shares were cancelled. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 2,275 | $262.70 | $597,642.50 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 26 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,245 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F21 · kind: The reporting person received 2,434 shares of common stock upon the net exercise of 4,819 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 110 shares of common stock underlying the stock appreciation rights representing the base value and 2,275 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on February 16, 2021 of $262.70. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | Disposition to issuerCommon Stock | 110 | $262.70 | $28,897.00 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 25 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,520 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F21 · kind: The reporting person received 2,434 shares of common stock upon the net exercise of 4,819 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 110 shares of common stock underlying the stock appreciation rights representing the base value and 2,275 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on February 16, 2021 of $262.70. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 4,819 | $5.95 | $28,673.05 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 24 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F21 · kind: The reporting person received 2,434 shares of common stock upon the net exercise of 4,819 stock appreciation rights under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"). The reporting person forfeited 110 shares of common stock underlying the stock appreciation rights representing the base value and 2,275 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on February 16, 2021 of $262.70. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 66 | $296.58 | $19,574.59 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 23 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,811 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F20 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $296.36 to $296.74, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 13 | $294.05 | $3,822.65 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 22 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,877 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 413 | $291.57 | $120,418.99 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 21 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,890 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F19 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $291.00 to $291.94, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 125 | $289.89 | $36,235.80 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 20 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,303 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F18 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $289.87 to $289.96, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 9 | $288.80 | $2,599.22 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 19 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,428 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F17 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $288.79 to $288.81, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 147 | $287.41 | $42,248.77 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 18 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,437 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F16 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $287.19 to $287.53, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 148 | $286.26 | $42,366.73 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 17 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,584 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F15 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $285.9150 to $286.70, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 59 | $285.30 | $16,832.96 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 16 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,732 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F14 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $284.89 to $285.54, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,204 | $284.25 | $342,235.07 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 15 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,791 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $283.89 to $284.88, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 955 | $283.43 | $270,677.85 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 14 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,995 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F12 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $282.89 to $283.88, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 653 | $282.13 | $184,233.37 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 13 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,950 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.85 to $282.79, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 522 | $281.64 | $147,015.14 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 12 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,603 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $280.81 to $281.80, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 156 | $280.71 | $43,790.07 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 11 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,125 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $279.8050 to $280.80, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 236 | $278.98 | $65,840.13 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 10 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,281 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $278.38 to $279.28, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 377 | $277.09 | $104,461.16 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 9 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,517 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.64 to $277.63, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 129 | $275.83 | $35,582.01 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 8 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,894 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.32 to $276.31, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 225 | $274.80 | $61,828.97 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 7 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,023 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.18 to $275.02, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 137 | $273.39 | $37,455.10 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 6 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,248 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.17 to $274.14, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 138 | $272.42 | $37,593.38 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 5 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,385 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.60 to $272.50, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 3,124 | $5.95 | $18,587.80 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 4 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 1,101 | $46.00 | $50,646.00 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 3 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 868 | $27.60 | $23,956.80 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 2 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 23:55 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 619 | $27.00 | $16,713.00 |
DisclosureSEC source: 0001209191-21-012107 · doc4.xml · nonDerivative · entry 1 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 1,250 shares acquired under the Issuer's Amended and Restated 2013 Employee Stock Purchase Plan, as amended, on January 31, 2021. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 22:08 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 9,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-063828 · doc4.xml · derivative · entry 2 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,300 Underlying: Common Stock · 9,300 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Company's Plan will vest on each of the first three (3) anniversaries of the Grant Date, subject to continued employment through each such vesting date. F3 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Company's Plan will vest on each of the first three (3) anniversaries of the Grant Date, subject to continued employment through each such vesting date. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 22:08 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 18,700 | $0.00 Strike: $129.70 | $0.00 |
DisclosureSEC source: 0001209191-20-063828 · doc4.xml · derivative · entry 1 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,700 Underlying: Common Stock · 18,700 shares Expires 2030-12-14 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on the first anniversary of the December 14, 2020 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 01:29 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,100 | $109.21 | $120,126.05 |
DisclosureSEC source: 0001209191-20-052526 · doc4.xml · nonDerivative · entry 16 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,561 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F16 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.89 to $109.45, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 01:29 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 3,145 | $108.39 | $340,888.75 |
DisclosureSEC source: 0001209191-20-052526 · doc4.xml · nonDerivative · entry 15 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,661 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F15 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.80 to $108.77, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 01:29 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 5,789 | $107.30 | $621,140.02 |
DisclosureSEC source: 0001209191-20-052526 · doc4.xml · nonDerivative · entry 14 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,806 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F14 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.72 to $107.72, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 01:29 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 9,915 | $106.17 | $1,052,689.43 |
DisclosureSEC source: 0001209191-20-052526 · doc4.xml · nonDerivative · entry 13 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,595 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.71 to $106.71, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:29 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001209191-20-052526 · doc4.xml · derivative · entry 17 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires 2029-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F17 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:29 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 551.38 | $117.07 | $64,547.63 |
DisclosureSEC source: 0001209191-20-052526 · doc4.xml · nonDerivative · entry 12 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,510 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F12 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.61 to $117.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:29 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 950.63 | $116.08 | $110,346.28 |
DisclosureSEC source: 0001209191-20-052526 · doc4.xml · nonDerivative · entry 11 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,062 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.61 to $116.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:29 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 1,002.51 | $115.23 | $115,520.83 |
DisclosureSEC source: 0001209191-20-052526 · doc4.xml · nonDerivative · entry 10 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,012 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.61 to $115.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:29 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 401 | $113.81 | $45,639.13 |
DisclosureSEC source: 0001209191-20-052526 · doc4.xml · nonDerivative · entry 9 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,015 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.61 to $114.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:29 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 726.82 | $113.02 | $82,148.10 |
DisclosureSEC source: 0001209191-20-052526 · doc4.xml · nonDerivative · entry 8 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,416 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.61 to $113.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:29 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 215.54 | $111.92 | $24,124.01 |
DisclosureSEC source: 0001209191-20-052526 · doc4.xml · nonDerivative · entry 7 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,143 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.61 to $112.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:29 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 2,343.11 | $110.97 | $260,023.82 |
DisclosureSEC source: 0001209191-20-052526 · doc4.xml · nonDerivative · entry 6 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,358 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.61 to $111.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:29 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 8,132.83 | $109.98 | $894,439.70 |
DisclosureSEC source: 0001209191-20-052526 · doc4.xml · nonDerivative · entry 5 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,701 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.61 to $110.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:29 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 6,661.4 | $109.07 | $726,546.24 |
DisclosureSEC source: 0001209191-20-052526 · doc4.xml · nonDerivative · entry 4 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,834 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.61 to $109.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:29 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 3,739.1 | $108.20 | $404,560.15 |
DisclosureSEC source: 0001209191-20-052526 · doc4.xml · nonDerivative · entry 3 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,496 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.61 to $108.60, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:29 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 275.69 | $107.22 | $29,559.67 |
DisclosureSEC source: 0001209191-20-052526 · doc4.xml · nonDerivative · entry 2 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,235 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.61 to $107.60, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2020 Filed Oct 1, 2020 01:29 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 25,000 | $5.95 | $148,750.00 |
DisclosureSEC source: 0001209191-20-052526 · doc4.xml · nonDerivative · entry 1 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 26, 2020 Filed Sep 29, 2020 22:12 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 38,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052368 · doc4.xml · derivative · entry 3 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,588 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3 · derivative.exercise_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested one (1) year from the September 26, 2019 grant date, subject to continued employment with the Company through the vesting date. F3 · derivative.expiration_date: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested one (1) year from the September 26, 2019 grant date, subject to continued employment with the Company through the vesting date. Read SEC document |
| September 26, 2020 Filed Sep 29, 2020 22:12 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 18,639 | $113.56 | $2,116,644.84 |
DisclosureSEC source: 0001209191-20-052368 · doc4.xml · nonDerivative · entry 2 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,510 Read SEC document |
| September 26, 2020 Filed Sep 29, 2020 22:12 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 38,588 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052368 · doc4.xml · nonDerivative · entry 1 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · balance_after: The reported ownership includes 1,250 shares acquired under the Company's Employee Stock Purchase Plan, as amended, on July 31, 2020. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 21:26 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 165,000 | $0.00 Strike: $19.08 | $0.00 |
DisclosureSEC source: 0001209191-20-048418 · doc4.xml · derivative · entry 1 Glenn Gregory M · CIK 0001342823 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2030-04-17 F1 · derivative.exercise_date: On April 17, 2020, the reporting person was granted an option to purchase 165,000 shares of common stock of Novavax, Inc. (the "Company") pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares will vest on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date, in each case subject to continued employment through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.